Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Keudell Morrison Wealth Management

Keudell Morrison Wealth Management grew its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 5.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,306 shares of the biotechnology company’s stock after purchasing an additional 241 shares during the period. Keudell Morrison Wealth Management’s holdings in Viking Therapeutics were worth $273,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Blue Trust Inc. bought a new stake in shares of Viking Therapeutics during the 3rd quarter valued at about $26,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in Viking Therapeutics in the second quarter valued at approximately $27,000. GAMMA Investing LLC grew its holdings in shares of Viking Therapeutics by 124.6% during the third quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 243 shares during the last quarter. Gilliland Jeter Wealth Management LLC acquired a new stake in shares of Viking Therapeutics during the 3rd quarter worth approximately $32,000. Finally, Massmutual Trust Co. FSB ADV lifted its holdings in shares of Viking Therapeutics by 84.3% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 553 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 253 shares during the last quarter. 76.03% of the stock is currently owned by institutional investors.

Viking Therapeutics Stock Up 0.5 %

VKTX traded up $0.36 during trading on Thursday, reaching $66.23. The stock had a trading volume of 517,780 shares, compared to its average volume of 4,492,506. Viking Therapeutics, Inc. has a 1-year low of $9.34 and a 1-year high of $99.41. The firm has a market capitalization of $7.38 billion, a price-to-earnings ratio of -70.83 and a beta of 1.00. The stock has a 50 day moving average of $64.55 and a two-hundred day moving average of $61.81.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. During the same period last year, the business earned ($0.23) EPS. On average, research analysts forecast that Viking Therapeutics, Inc. will post -0.98 EPS for the current fiscal year.

Analyst Ratings Changes

VKTX has been the subject of a number of recent research reports. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. JPMorgan Chase & Co. began coverage on shares of Viking Therapeutics in a research report on Wednesday, September 11th. They set an “overweight” rating and a $80.00 price target for the company. Raymond James lifted their price objective on shares of Viking Therapeutics from $116.00 to $118.00 and gave the company a “strong-buy” rating in a research report on Thursday, July 25th. Oppenheimer restated an “outperform” rating and issued a $138.00 price target on shares of Viking Therapeutics in a research note on Wednesday, September 25th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $105.00 price target on shares of Viking Therapeutics in a report on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $109.80.

Insider Activity at Viking Therapeutics

In other news, CFO Greg Zante sold 131,687 shares of the business’s stock in a transaction on Monday, October 28th. The stock was sold at an average price of $76.61, for a total transaction of $10,088,541.07. Following the sale, the chief financial officer now directly owns 149,366 shares of the company’s stock, valued at $11,442,929.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Greg Zante sold 131,687 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $76.61, for a total value of $10,088,541.07. Following the completion of the sale, the chief financial officer now owns 149,366 shares in the company, valued at approximately $11,442,929.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director J Matthew Singleton sold 20,786 shares of Viking Therapeutics stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.53, for a total transaction of $1,195,818.58. Following the transaction, the director now owns 9,500 shares in the company, valued at approximately $546,535. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 525,473 shares of company stock valued at $37,088,158 over the last ninety days. Insiders own 4.70% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.